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Abstract
Background: Disruption of cellular antioxidation systems should be an effective method for control of fungal
pathogens. Such disruption can be achieved with redox-active compounds. Natural phenolic compounds can serve
as potent redox cyclers that inhibit microbial growth through destabilization of cellular redox homeostasis and/or
antioxidation systems. The aim of this study was to identify benzaldehydes that disrupt the fungal antioxidation
system. These compounds could then function as chemosensitizing agents in concert with conventional drugs or
fungicides to improve antifungal efficacy.
Methods: Benzaldehydes were tested as natural antifungal agents against strains of Aspergillus fumigatus, A. flavus,
A. terreus and Penicillium expansum, fungi that are causative agents of human invasive aspergillosis and/or are
mycotoxigenic. The yeast Saccharomyces cerevisiae was also used as a model system for identifying gene targets of
benzaldehydes. The efficacy of screened compounds as effective chemosensitizers or as antifungal agents in
formulations was tested with methods outlined by the Clinical Laboratory Standards Institute (CLSI).
Results: Several benzaldehydes are identified having potent antifungal activity. Structure-activity analysis reveals
that antifungal activity increases by the presence of an ortho-hydroxyl group in the aromatic ring. Use of deletion
mutants in the oxidative stress-response pathway of S. cerevisiae (sod1Δ, sod2Δ, glr1Δ) and two mitogen-activated
protein kinase (MAPK) mutants of A. fumigatus (sakAΔ, mpkCΔ), indicates antifungal activity of the benzaldehydes is
through disruption of cellular antioxidation. Certain benzaldehydes, in combination with phenylpyrroles, overcome
tolerance of A. fumigatus MAPK mutants to this agent and/or increase sensitivity of fungal pathogens to
mitochondrial respiration inhibitory agents. Synergistic chemosensitization greatly lowers minimum inhibitory (MIC)
or fungicidal (MFC) concentrations. Effective inhibition of fungal growth can also be achieved using combinations
of these benzaldehydes.
Conclusions: Natural benzaldehydes targeting cellular antioxidation components of fungi, such as superoxide
dismutases, glutathione reductase, etc., effectively inhibit fungal growth. They possess antifungal or
chemosensitizing capacity to enhance efficacy of conventional antifungal agents. Chemosensitization can reduce
costs, abate resistance, and alleviate negative side effects associated with current antifungal treatments.
Background
A number of different cellular targets of conventional
antifungal drugs have already been identified. Examples
include mitochondrial respiration, cell wall/membrane
integrity, cell division, signal transduction, and macro-
molecular synthesis, etc. [1]. However, conventional
antifungal drugs (including fungicides) also cause serious
mammalian cytotoxicity, partly through the intracellular
production of reactive oxygen species (ROS) [2].
Emerging resistance to currently available antifungal
drugs and a deficiency in discovery of new ones engen-
der urgency for development of new antifungal agents
and/or alternative therapies for control of fungal patho-
gens [3-7].
Natural compounds that do not have any significant
medical or environmental impact are a potential source
of antimycotic agents, either in their nascent form or as
template structures for more effective derivatives [8,9].
Prior studies showed that analogs of benzoic or cin-
namic acids, common phenolics found in edible plants,
inhibit biosynthesis of mycotoxins and growth of various
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is that these phenolics can be potent redox cyclers that
inhibit microbial growth through disruption of cellular
redox homeostasis and/or antioxidation systems [13,14].
From a clinical perspective, the functions of antioxida-
tion systems [e. g., mitogen-activated protein kinases
(MAPKs)], two-component histidine kinase and antioxi-
dation enzymes [e.g., superoxide dismutases (SODs), cat-
alase, etc.], have been implicated as factors important to
the virulence of fungal pathogens [15,16]. In Aspergillus
fumigatus, Cu,Zn-SOD detoxifies ROS produced by host
defense systems [17]. Fungi require well defined regula-
tion of expression of antioxidation systems, not only for
protection from host defense responses, but also for
maintaining redox homeostasis needed for normal fun-
gal growth [18,19]. Because of this pivotal role, destabili-
zation of antioxidation systems can be an effective way
to control fungal pathogens. Such destabilization may be
possible with redox-active compounds.
Inhibitors of the mitochondrial respiratory chain
(MRC), such as antimycin A or mucidin, disrupt cellular
energy production in fungi [20,21], decreasing cell viabi-
lity. Coinciding with this disruption is an abnormal
release of electrons from the chain. This surfeit of elec-
trons further stresses cellular components through oxi-
dative damage resulting in apoptosis or necrosis [21,22].
As indicated above, the cellular antioxidation system [e.
g., cytosolic superoxide dismutase (Cu,Zn-SOD), mito-
chondrial superoxide dismutase (Mn-SOD), glutathione
reductase, etc.] plays an important defensive role in pro-
tecting fungal cells from such oxidative species [23,24].
Other studies have also shown that antimicrobial
activity of a variety of drugs can be linked to cellular
oxidative stress. Examples include ciprofloxacin, a fluor-
oquinolone antibiotic inhibiting DNA topoisomerases
([25] and references therein). After treatment of cipro-
floxacin, the level of ROS was increased in bacterial
pathogens. However, application of antioxidants, such as
reduced glutathione (GSH) or ascorbic acid, reversed
the toxicity of fluoroquinolones. In addition, transfection
of SOD genes into bacteria also resulted in greater sur-
vival of cells exposed to these drugs [25], indicating
ROS (i.e., superoxides, peroxides, etc.) are involved in
antimicrobial activity of ciprofloxacin. Amphotericin B
(AMB), a polyene antifungal drug, is another example.
Although AMB is known as a fungicidal drug, studies
have shown that addition of antioxidants, such as GSH,
cysteine, etc., could revive endospores of Coccidioides
immitis treated with AMB ([26] and references therein).
Other data also indicate involvement of cellular oxida-
tive stress in the antifungal action of AMB [27,28].
Co-application of certain types of compounds can
enhance effectiveness of conventional antimicrobial
agents through a process termed chemosensitization. In
this case, a chemosensitizing agent functions by debili-
tating the ability of a pathogen to completely activate a
defense response to an antimicrobial agent [29,30]. A
chemosensitizing agent does not necessarily require a
great degree of antimicrobial potency, itself, to be
effective.
The chief value of chemosensitization, especially by
safe natural compounds, is lowering of dosage levels of
commercial drugs required for control of pathogens;
thus, lowering costs and risks of negative side effects.
Redox-active natural compounds that destabilize the
fungal antioxidation system could act as potent chemo-
sensitizing agents when co-applied with oxidative stress
drugs, such as MRC inhibitors, for control of fungal
pathogens. Thus, chemosensitization could make the
use of toxic antifungal drugs or fungicides more attrac-
tive as a chemotherapeutic strategy, and to overcome
development of pathogen resistance to conventional
antimicrobial agents.
Filamentous fungi in the genus Aspergillus are notable
etiological agents of a highly debilitating human disease,
invasive aspergillosis [31]. Among these are A. fumiga-
tus, A. terreus and A. flavus, ubiquitous opportunistic
pathogens. A. flavus also produces hepatocarcinogenic
aflatoxins that are a major food safety issue in that they
can contaminate a variety of edible crops and their by-
products [32]. Likewise, another mycotoxin, patulin [4-
hydroxy-4H-furo (3,2C) pyran-2(6H)-one], that can con-
taminate fruits, causes serious acute/chronic cellular or
target-organ toxicity in mammals by disrupting cellular
[33,34] and enzymatic [35,36] processes. Patulin is most
commonly produced by fungi in the genera Aspergillus
and Penicillium [37,38]. Among these, P. expansum is of
highest food safety concern with regard to patulin-
production.
The yeast Saccharomyces cerevisiae is a useful model
system for identifying antifungal agents and their gene
targets in view that: (1) the genome of S. cerevisiae has
been sequenced and well annotated ([39], accessed
March 1, 2011); (2) S. cerevisiae gene deletion mutants
have proven to be very useful for identifying the
mechanism/target genes of antimicrobial agents [40];
and (3) many genes in S. cerevisiae are orthologs of
genes of fungal pathogens [41]. For example, we recently
confirmed structural homology of signal transduction
and antioxidation genes between S. cerevisiae and the
filamentous fungus A. flavus [42].
In this study, we identify safe natural phenolics, which
can specifically disrupt the fungal antioxidation system.
As potent redox cyclers, phenolic compounds can effec-
tively debilitate the cellular redox homeostasis/antioxi-
dation system in fungi, resulting in the suppression of
fungal growth. We describe a bioassay, using S. cerevi-
siae as a model, which provides a framework for
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compounds and for identifying promising molecular tar-
gets. In this study, we focus on effectiveness of struc-
tural analogs of benzaldehyde to identify: (1) the most
effective antifungal target in the mitochondrial respira-
tory chain (MRC); (2) the most effective analogs as anti-
fungal agents; and (3) the fungal antioxidation system as
the target of the benzaldehydes. In addition, we examine
if benzaldehydes can serve as chemosensitizing agents or
as antifungal agents, in combination amongst them-
selves, at the micromolar level.
Methods
Microorganisms
Aspergillus fumigatus AF293 (wild type), and A. fumiga-
tus MAPK deletion mutants sakAΔ and mpkCΔ [43,44]
were grown at 35°C on potato dextrose agar (PDA). A.
terreus UAB673, UAB680 and UAB698, clinical strains
from aspergillosis patients, were obtained from Centers
for Disease Control and Prevention, Atlanta, GA, and
were grown at 35°C on PDA. Also, A. flavus NRRL3357
and Penicillium expansum NRRL974, obtained from the
National Center for Agricultural Utilization and
Research, USDA-ARS, Peoria, IL, were grown at 28°C
on PDA. Temperatures used were the optimum tem-
peratures for each strain. Saccharomyces cerevisiae wild
type BY4741 (Mat a his3Δ1l e u 2 Δ0m e t 1 5 Δ0u r a 3 Δ0)
and selected single gene deletion mutants, i.e., cytosolic
superoxide dismutase (Cu,Zn-SOD) mutant (sod1Δ),
mitochondrial superoxide dismutase (Mn-SOD) mutant
(sod2Δ) and glutathione reductase mutant (glr1Δ), were
obtained from Invitrogen (Carlsbad, CA) and Open Bio-
systems (Huntsville, AL; [39], accessed March 1, 2011).
Yeast strains were cultured on SG (Yeast nitrogen base
without amino acids 0.67%, glucose 2% with appropriate
supplements: uracil 0.02 mg/ml, amino acids 0.03 mg/
ml) agar at 30°C.
Chemicals
Benzaldehyde (basal compound) and its structural analogs
(twenty-one new benzaldehyde derivatives), i.e., cinnamal-
dehyde, 2-hydroxy-3-methoxybenzaldehyde (o-vanillin), 2-
hydroxy-5-methoxybenzaldehyde, 2-methylbenzaldehyde
(o-tolualdehyde), 3-methylbenzaldehyde (m-tolualdehyde),
4-methylbenzaldehyde (p-tolualdehyde), 2-methoxybenzal-
dehyde (o-anisaldehyde), 3-methoxybenzaldehyde (m-ani-
saldehyde), 4-methoxybenzaldehyde (p-anisaldehyde), 2,3-
dimethoxybenzaldehyde, 2,4-dimethoxybenzaldehyde, 2,5-
dimethoxybenzaldehyde, 3,5-dimethoxybenzaldehyde,
2,4,5-trimethoxybenzaldehyde, 4-hydroxy-2-methoxyben-
zaldehyde, 3,5-dimethoxy-4-hydroxybenzaldehyde (syrin-
galdehyde), 3,5-dimethoxy-4-hydroxycinnamaldehyde, 4-
methoxy-2-methylbenzaldehyde, 2-hydroxy-5-methylben-
zaldehyde, 2,4-dimethylbenzaldehyde, 4-diethylamino-2-
hydroxybenzaldehyde, two phenolics (cell wall/membrane
integrity disruptors) [2,3-dihydroxybenzaldehyde (2,3-D),
thymol], strobilurins [pyraclostrobin (PCS), kresoxim
methyl (Kre-Me)] and other chemicals [antimycin A
(AntA), carboxin, thenoyltrifluoroacetone (TTFA), rote-
none, 3-nitropropionic acid (3-NPA), benzhydroxamic
acid (BHAM), salicylhydroxamic acid (SHAM), potassium
cyanide (KCN), fludioxonil, glutathione (GSH, reduced
f o r m ;G S S G ,o x i d i z e df o r m ) ,d i m e t h y l d i t h i o c a r b a m a t e
(DDC)] were procured from Sigma Co. (St. Louis, MO,
USA). Each compound was dissolved in dimethylsulfoxide
(DMSO; absolute DMSO amount: < 2% in media), except
glutathione, which was dissolved in water, before incor-
poration into culture media. In all tests, control plates (i.e.,
“No treatment”) contained DMSO at levels equivalent to
that of cohorts receiving antifungal agents, within the
same set of experiments (See Figures).
Antifungal bioassays
Plate (agar) bioassay
Measurement of sensitivities of filamentous fungi to the
structural analogs of benzaldehyde was based on percent
radial growth of treated compared to control fungal
colonies (Test concentrations: 0, 0.5, 1.0, 1.5, 2.0, 2.5,
3.0 mM). The percent inhibition of growth was calcu-
lated using the Vincent equation [45] [% inhibition =
100 (C-T)/C; where C = diameter of fungal colony on
control plate (receiving only DMSO), and T = diameter
of fungal colony on the treated plate]. Minimum Inhibi-
tory Concentration (MIC) values on agar plates were
based on triplicate assays and defined as the lowest con-
centration of agent where no fungal growth was visible
on the plate. For the above assays, fungal conidia (5 ×
10
3) were diluted in phosphate buffered saline and
applied as a drop onto the center of PDA plates with or
without antifungal compounds. Growth was observed
for three to seven days.
Petri plate-based yeast dilution bioassays were per-
formed on the wild type and antioxidation mutants
(sod1Δ, sod2Δ, glr1Δ) to assess effects of screened com-
pounds on the antioxidation system. Yeast strains were
exposed to 0.1 to 1.5 mM of seven benzaldehyde ana-
logs screened. These assays were performed in duplicate
on SG agar following previously described protocols [46]
Microdilution (microtiter) bioassay
Levels and types of compound interactions between
antifungal agents were based on Fractional Inhibitory
Concentration Indices (FICI) [47], where FICI = (MIC
of compound A in combination with compound B/MIC
of compound A, alone) + (MIC of compound B in com-
bination with compound A/MIC of compound B,
alone). Compound interactions were defined as synergis-
tic (FICI ≤ 0.5), additive (0.5 < FICI ≤ 1), neutral (1 <
FICI ≤ 2) or antagonistic (2 < FICI).
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use in calculating FICIs, triplicate assays (4 × 10
4 conidia/
ml) were performed using a broth microdilution according
to methods outlined by the Clinical Laboratory Standards
Institute (CLSI) M38-A [48]. RPMI 1640 medium (Sigma
Co.) was supplemented with 0.03% L-glutamine and buf-
fered with 0.165 mM 3-[N-morpholino] propanesulfonic
acid. Concentrations of test compounds used for chemo-
sensitization assays were as described in the text.
Formulation studies of benzaldehydes
Formulation studies included o-vanillin, 2-hydroxy-5-
methoxybenzaldehyde, cinnamaldehyde, which showed the
highest antifungal activities (Group A benzaldehydes: See
below) and two additional phenolic agents, 2,3-dihydroxy-
benzaldehyde (2,3-D) and thymol, found in a prior study
to disrupt cell wall/membrane integrity [46]. Compounds
were tested either singularly or combined in formulations
that included all five compounds. Antifungal efficacies of
singular compounds vs. formulations were compared.
Treatments included the compounds at 2, 4, 8, 16, 32, 64
or 128 μg/ml alone, or all together in equal amounts at
these same concentrations (e.g., mixtures of 2 μg/ml, each,
4 μg/ml, each, etc., of all five compounds), to determine
MICs and Minimum Fungicidal Concentrations (MFCs) of
the compounds individually and as formulations. All assays
were performed in triplicate in 96-well microtiter plates
(48 hrs incubation for determining MICs).
The level of antifungal efficacy of a formulation was
evaluated by determining ratio of MFC/MIC. To obtain
MFC values, the entire volume of each well (200 μlp e r
well) from microtiter plates (at 48 hrs of incubation)
was spread onto independent PDA plates, and cultured
for an additional 48 hrs at temperatures respective for
each fungus (See above). MFC was defined as the lowest
concentration of agent where > 99.9% fungal death
occurred, as determined by cell growth on the agar
plate. If MFCFORMULATION/MICFORMULATION was ≤ 4,
the formulation was defined as fungicidal, whereas if
MFCFORMULATION/MICFORMULATION was > 4, the for-
mulation was defined as fungistatic [49].
Assessment of compound formulations was measured
by formulation efficacy (FE), i.e., FEMIC or FEMFC. Respec-
tive FEs were calculated, as follows: FEMIC= (MIC of com-
pound A, alone/MICFORMULATION)o rF E MFC =( M F Co f
compound A, alone/MFCFORMULATION), respectively. We
defined FE as (a) no effect, if FE ≤ 1, (b) low (L), if 1 < FE
< 4, or (c) high (H), if FE ≥ 4( S e ea l s ot a b l e4 ) .
Results
Complexes II and III as the most effective antifungal
targets in the mitochondrial respiratory chain (MRC)
Since various antifungal agents inhibit different compo-
nents of the MRC at varying levels, we initially
attempted to identify the most effective antifungal target
(s) within this chain. We tested eleven conventional
antifungal agents, which disrupt the functions of com-
plexes I, II, III, IV or alternative oxidases (AOX) in the
MRC, using A. fumigatus AF293 as a representative fun-
gal pathogen (Figure 1A).
Targeting MRC complex II of A. fumigatus AF293
with thenoyltrifluoroacetone (TTFA) or carboxin, or
complex III with antimycin A (AntA) or strobilurins [i.
e., kresoxim methyl (Kre-Me)/pyraclostrobin (PCS)],
resulted in greater inhibition of fungal growth (Vincent
equation: 36% - 84%) compared to targeting other MRC
complexes (Vincent eq.: 0% - 14%) (Figure 1B). Results
also indicated that complex III inhibitors possessed
higher antifungal activity (Vincent eq.: 60% - 84%) than
complex II inhibitors (Vincent eq.: 36% - 48%). In our
test, the complex II inhibitor 3-nitropropionic acid (3-
NPA) had no discernable growth inhibitory effect on A.
fumigatus. Neither did the complex I inhibitor, rotenone
(Rot.), AOX inhibitors, benz- or salicyl-hydroxamic
acids (BHAM, SHAM), nor complex IV inhibitors potas-
sium cyanide (KCN) and sodium azide (Na-azide) (Fig-
ure 1B). DMSO is a good solvent for polar and non-
polar compounds, is miscible in varying organic sub-
stances and is widely used to enhance absorption for
drug-delivery [50]. We considered that the individual
MRC inhibitors tested were absorbed at equivalent
levels by fungal cells. However, future studies should
specifically examine if these inhibitors reach targets
within cells at the same rates and levels.
To confirm if inhibitors of complexes II and III can
function synergistically to disrupt fungal mitochondrial
respiration, TTFA/carboxin (complex II inhibitors) and
AntA/Kre-Me/PCS (complex III inhibitors) were co-
applied against six strains of filamentous fungal patho-
gens, i.e., A. fumigatus,t h et h r e eA. terreus strains, A.
flavus,a n dP. expansum (Table 1). Co-treatment of
complex II and III inhibitors greatly increased their
antifungal activities in comparison to each compound,
alone. Most compound FICI-based interactions were
either additive or synergistic, depending on types of
drug combinations and/or strains tested. For example,
interactions between carboxin with any of the complex
III inhibitors were synergistic in all fungi tested, except
with AntA in A. flavus, where it was additive. Interac-
tions between TTFA and the complex III inhibitors
were, for the most part, synergistic as well. The excep-
tions were additive interactions with AntA in A. ter-
reus UAB673 and A. fumigatus and a neutral
interaction in A. flavus. Collectively, results indicated
that targeting complexes II and III of the MRC, simul-
taneously, could prove to be an effective antifungal
strategy, in that their inhibitors mainly act
synergistically.
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antifungal activities: structure-activity relationships
Next, we examined antifungal efficacy of 21 analogs of
benzaldehyde against the six different strains/species of
filamentous fungi, in in vitro agar plate bioassays. Seven
analogs (Figure 2A) were found that had higher antifun-
gal activity (i.e., MIC ≤ 3.0 mM cutoff) than other com-
pounds. The screened compounds were categorized into
four groups, based on level of antifungal activity, as fol-
lows (MICs based on average values obtained from all
six filamentous fungi): Group A (0.5 < MIC ≤ 1.0 mM)-
cinnamaldehyde, 2-hydroxy-3-methoxybenzaldehyde (o-
vanillin) and 2-hydroxy-5-methoxybenzaldehyde; Group
B( 1 . 0<M I C≤ 2.0 mM)- 2,5-dimethoxybenzaldehyde
and 3,5-dimethoxybenzaldehyde; Group C (2.0 < MIC ≤
3.0 mM)- 2-methoxybenzaldehyde (o-anisaldehyde) and
2,3-dimethoxybenzaldehyde; and Group D (MIC > 3.0
mM)- the remaining 14 benzaldehyde analogs.
Structure-activity relationships were also found among
the screened compounds. Firstly, the ortho-hydroxyl (2-
OH) group on the aromatic ring, in general, results in
higher antifungal activity compared with an ortho-meth-
oxy (2-OMe) group (Table 2). For example, 2-hydroxy-
3-methoxybenzaldehyde (o-vanillin; MIC 0.67 mM) has
> 3-fold antifungal activity (viz., lower MIC) than 2,3-
dimethoxybenzaldehyde (MIC 2.5 mM). Likewise, 2-
hydroxy-5-methoxybenzaldehyde (MIC 0.58 mM) has
again, almost three-fold greater antifungal activity than
2,5-dimethoxybenzaldehyde (MIC 1.5 mM). A similar
comparative trend can be seen with the MICs of 2-
hydroxy-3-methoxybenzaldehyde or 2-hydroxy-5-meth-
oxybenzaldehyde against that of 2-methoxybenzaldehyde
(MIC 2.42 mM) (Table 2). [Note: Since 2-hydroxyben-
zaldehyde (Salicylaldehyde) is a volatile, it was not
included in this study but does have antifungal and che-
mosensitizing activity [51]].
Antithetically, a methyl group, in general, reduced anti-
fungal activities of benzaldehyde analogs (All methyl-
containing compounds belong to the least active, Group
D compounds). For example, 2-hydroxy-5-methylbenzal-
dehyde, generated by simple deoxygenation of the meth-
oxy group of 2-hydroxy-5-methoxybenzaldehyde, showed
Treatment
Growth 
inhibition (%)
AOX I II III IV Mitochondrial target
None Rot. Carb. TTFA 3-NPA BHAM SHAM AntA Kre-Me PCS KCN Na-azide
00 0 14 14 36 48 4 60 72 84 8
(A)
   CoQ
  CytC
   NADH 
+H +
   NAD+
   H+
FADH2
FAD
   H+    H+
   H+
1/2O2
  H2O
ADP
+ Pi
   ATP
   e-
   e-
Intermembrane
space
   Matrix
   Complex I  Complex II    Complex III    Complex IV    Complex V
   AOX
(B)
Figure 1 Targeting the mitochondrial respiratory chain. (A) Schematic representation of mitochondrial respiratory chain (Adapted from [78]
and [22]. CoQ, Coenzyme Q; CytC, Cytochrome C; e
-, Electrons; Dashed lines, Electron flow. (B) Differential antifungal efficacy of inhibitors (0.1
mM) of mitochondrial respiration targeting complexes I to IV and alternative oxidases (AOX), tested in Aspergillus fumigatus AF293. Results
indicated that targeting complex II or III by using carboxin, TTFA, antimycin A, kresoxim methyl or pyraclostrobin resulted in higher inhibition of
fungal growth than targeting other complexes (%: Growth inhibition rate, SD < 5%). Rot, Rotenone; Carb, Carboxin; TTFA,
Thenoyltrifluoroacetone; 3-NPA, 3-Nitropropionic acid; BHAM, Benzhydroxamic acid; SHAM, Salicylhydroxamic acid; AntA, Antimycin A; Kre-Me,
Kresoxim methyl; PCS, Pyraclostrobin; KCN, Potassium cyanide; Na-azide, Sodium azide. I to IV, complexes I to IV of mitochondrial respiratory
chain; AOX, Alternative oxidases.
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1
Combinations A MIC alone MIC combined FICI MIC alone MIC combined FICI MIC alone MIC combined FICI
Strains A. terreus UAB698 A. terreus UAB680 A. terreus UAB673
Kre-Me
Carboxin
> 1.6
2
> 128
3
0.2 - 0.4
8-1 6
0.19 S > 1.6
> 128
0.2 - 0.4
4-8
0.16 S > 1.6
> 128
0.2 - 0.4
8-1 6
0.19 S
Pyraclostrobin
Carboxin
> 1.6
> 128
0.0 - 0.05
4-8
0.05 S > 1.6
> 128
0.0 - 0.05
4-8
0.05 S > 1.6
> 128
0.0 - 0.05
4-8
0.05 S
AntimycinA
Carboxin
> 1.6
> 128
0.4 - 0.8
8-1 6
0.31 S > 1.6
> 128
0.4 - 0.8
16 - 32
0.38 S > 1.6
> 128
0.4 - 0.8
16 - 32
0.38 S
Strains A. flavus NRRL3357 A. fumigatus AF293 P. expansum NRRL974
Kre-Me
Carboxin
0.4 - 0.8
> 128
0.0 - 0.05
0.5 - 1
0.07 S > 1.6
> 128
0.0 - 0.05
2-4
0.03 S 0.4 - 0.8
32 - 64
0.0 - 0.05
0.5 - 1
0.08 S
Pyraclostrobin
Carboxin
0.4 - 0.8
> 128
0.0 - 0.05
0.125 - 0.25
0.06 S 0.8 - 1.6
32 - 64
0.0 - 0.05
1-2
0.06 S 0.4 - 0.8
2-4
0.0 - 0.05
0.25 - 0.5
0.19 S
AntimycinA
Carboxin
0.4 - 0.8
> 128
0.2 - 0.4
4-8
0.53 A 0.8 - 1.6
> 128
0.2 - 0.4
4-8
0.28 S 0.4 - 0.8
> 128
0.05 - 0.1
2-4
0.14 S
Combinations B MIC alone MIC Combined FICI MIC alone MIC combined FICI MIC alone MIC combined FICI
Strains A. terreus UAB698 A. terreus UAB680 A. terreus UAB673
Kre-Me
TTFA
> 1.6
2
> 128
3
0.2 - 0.4
4-8
0.16 S > 1.6
> 128
0.2 - 0.4
16 - 32
0.25 S > 1.6
> 128
0.2 - 0.4
16 - 32
0.25 S
Pyraclostrobin
TTFA
> 1.6
> 128
0.1 - 0.2
4-8
0.09 S > 1.6
> 128
0.2 - 0.4
4-8
0.16 S > 1.6
> 128
0.2 - 0.4
4-8
0.16 S
AntimycinA
TTFA
> 1.6
> 128
0.4 - 0.8
32 - 64
0.50 S > 1.6
> 128
0.4 - 0.8
32 - 64
0.50 S > 1.6
> 128
0.8 - 1.6
32 - 64
0.75 A
Strains
Compounds
A. flavus NRRL3357 A. fumigatus AF293 P. expansum NRRL974
Kre-Me
TTFA
> 1.6
> 128
0.4 - 0.8
16 - 32
0.38 S > 1.6
> 128
0.2 - 0.4
8-1 6
0.19 S > 1.6
16 - 32
0.4 - 0.8
4-8
0.50 S
Pyraclostrobin
TTFA
> 1.6
> 128
0.4 - 0.8
8-1 6
0.31 S > 1.6
> 128
0.1 - 0.2
4-8
0.09 S > 1.6
4-8
0.05 - 0.1
1-2
0.28 S
AntimycinA
TTFA
> 1.6
> 128
> 1.6
> 128
1.00 N > 1.6
> 128
0.8 - 1.6
32 - 64
0.75 A > 1.6
> 128
0.00 - 0.05
8-1 6
0.08 S
1 Compound interactions were determined as Fractional Inhibitory Concentration Indices (FICI), described by Isenberg ([47]; See also Methods). For calculation purposes, the higher concentration in each column was
used. A, additive; N, neutral; S, synergistic. Complex II inhibitors (μg/ml)- Carboxin, Thenoyltrifluoroacetone (TTFA); Complex III inhibitors (mM)- Kresoxim methyl (Kre-Me), Pyraclostrobin, Antimycin A. Drug
combinations for calculating FIC indices were: (Combinations A) Kre-Me + carboxin, pyraclostrobin + carboxin, and antimycin A + carboxin, and (Combinations B) Kre-Me + TTFA, pyraclostrobin + TTFA, and antimycin
A + TTFA.
2 Since antifungal test was performed up to 1.6 mM of strobilurins or antimycin A (See Methods), 3.2 mM (doubling of 1.6 mM) was used for calculation purposes.
3 Since antifungal test was performed up to 128 μg/ml of carboxin or TTFA (See Methods), 256 μg/ml (doubling of 128 μg/ml) was used for calculation purposes.
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No 3,5-D 3,5-D (1.0 mM)
100 10-110-210-310-410-5 100 10-110-210-310-410-5
No GSH/GSSG
GSH
GSSG
No GSH/GSSG
GSH
GSSG
WT
glr1Δ
(C) (D)
WT
sod2Δ
sod1Δ
glr1Δ
Sensitive 
mutants
No treatment
100 10-110-210-310-410-5
[None]
Cinnamaldehyde
100 10-110-210-310-410-5
0.1 mM
[sod2Δ, sod1Δ]
o-Vanillin
100 10-110-210-310-410-5
0.2 mM
[sod1Δ]
2-OH-5-Methoxy 
benzaldehyde
100 10-110-210-310-410-5
0.2 mM
[sod2Δ, sod1Δ]
2,5-Dimethoxy 
benzaldehyde
100 10-110-210-310-410-5
0.8 mM
[sod2Δ, sod1Δ]
2,3-Dimethoxy 
benzaldehyde
100 10-110-210-310-410-5
1.5 mM
[sod1Δ]
2-Methoxy 
benzaldehyde
100 10-110-210-310-410-5
1.5 mM
[sod2Δ]
3,5-Dimethoxy 
benzaldehyde
100 10-110-210-310-410-5
0.8 mM
[sod2Δ,
sod1Δ, glr1Δ]
(B)
No treatment
3,5-D
(0.8 mM)
0% 0% 0%
66% 100%
AF293 sakAΔ mpkCΔ
100%
H O
(1)
H O
OH
OCH3
(2)
H O
OH
H3CO
(3)
H O
OCH3
(4)
H O
OCH3
OCH3
(5)
H O
OCH3
H3CO
(6)
H O
H3CO OCH3
(7) H O (8)
Figure 2 Structure-activity relationships of the benzaldehydes in targeting the oxidative-stress response system of fungi. (A)
Benzaldehyde and its structural analogs used in this study. (1) Benzaldehyde (parent compound), (2) trans-Cinnamaldehyde, (3) 2-Hydroxy-5-
methoxybenzaldehyde, (4) 2-Hydroxy-3-methoxybenzaldehyde (o-Vanillin), (5) 3,5-Dimethoxybenzaldehyde, (6) 2,5-Dimethoxybenzaldehyde, (7) 2-
Methoxybenzaldehyde, (8) 2,3-Dimethoxybenzaldehyde. (B) Responses of Saccharomyces cerevisiae wild type and antioxidation mutant strains to
the treatment of benzaldehyde analogs. Sensitive mutants in each treatment were designated under the yeast dilution bioassay (10
0 to 10
5
indicates the dilution rate for spotting onto agar plate). (C) Recovery of the growth of yeast cells treated with 3,5-dimethoxybenzaldehyde (3,5-
D) by reduced form of glutathione (GSH; 0.1 mM), but not by oxidized form of glutathione (GSSG; 0.1 mM). (D) Sensitive responses of A.
fumigatus MAPK mutants (sakAΔ and mpkCΔ) to 3,5-dimethoxybenzaldehyde (3,5-D)(%: Growth inhibition rate, SD < 5%).
Table 2 Antifungal activities (MIC mM) of benzaldehyde derivatives tested on agar against filamentous fungi
Compound A. fumigatus
AF293
A. terreus
UAB673
A. terreus
UAB680
A. terreus
UAB698
A. flavus
NRRL3357
P. expansum
NRRL974
Mean
MIC
Cinnamaldehyde 1.0 0.5 0.5 0.5 0.5 0.5 0.58 ± 0.20
1
2-Hydroxy-5-methoxy-
benzaldehyde
0.5 0.5 0.5 0.5 0.5 1.0 0.58 ± 0.20
1
2-Hydroxy-3-methoxy-
benzaldehyde (o-Vanillin)
0.5 0.5 0.5 0.5 1.0 1.0 0.67 ± 0.26
1
3,5-Dimethoxybenzaldehyde 1.0 1.0 1.0 1.0 1.5 1.5 1.17 ± 0.26
1
2,5-Dimethoxybenzaldehyde 1.5 1.5 1.5 1.0 1.5 2.0 1.50 ± 0.32
1
2-Methoxybenzaldehyde
(o-Anisaldehyde)
2.0 2.5 2.5 2.5 2.5 2.5 2.42 ± 0.20
1
2,3-Dimethoxybenzaldehyde 2.5 2.5 2.0 2.0 3.0 3.0 2.50 ± 0.45
1
Benzaldehyde
(Basal structure)
> 35.0 > 35.0 > 35.0 > 35.0 > 35.0 > 35.0 > 35.0
1 P < 0.0005 (Student’s t test for paired data, i.e., vs. mean MIC of benzaldehyde).
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Page 7 of 16a much higher MIC (> 3.0 mM) than the latter (MIC 0.58
mM). Likewise, the MIC of 2-methylbenzaldehyde
exceeds 3.0 mM, while that of 2-methoxybenzaldehyde
was 2.42 mM.
Of note is that 2,3- and 2,5-dimethoxybenzaldehyde
(MICs: 2.50 and 1.50 mM, respectively) have higher
antifungal activity than 2,4-dimethoxybenzaldehyde
(MIC: > 3.0 mM). This result is similar to the character-
istics of quinone derivatives, where functions of
enzymes/proteins are inhibited mostly by those deriva-
tives having an ortho-o rpara-quinonoid structure. For
example, acetaminophen, a benzoquinoid, is a known
inhibitor of a macrophage migration inhibitory factor
t a u t o m e r a s e[ 5 2 ] .T h i st y p eo fi n h i b i t o r yp o t e n t i a lm a y
explain why a methoxy group in an ortho-o rpara-posi-
tion also results in relatively higher antifungal activity
than that in a meta-position.
Effect of benzaldehydes on fungal antioxidation: S.
cerevisiae antioxidation mutants
Yeast dilution bioassays were performed using S. cerevi-
siae wild type and antioxidation mutants, sod1Δ, sod2Δ
and glr1Δ, against the seven most active benzaldehyde
analogs. Both the sod1Δ and sod2Δ mutants showed
reduced cell growth as represented by a two log10 less
dilution of yeast cells before appearance of a colony
when treated with cinnamaldehyde, 2-hydroxy-5-meth-
oxybenzaldehyde, 2,5-dimethoxybenzaldehyde and 3,5-
dimethoxybenzaldehyde, compared to the wild type (Fig-
ure 2B). Additionally, the sod1Δ mutant showed this
same level of sensitivity to o-vanillin and 2,3-dimethoxy-
benzaldehyde, while sod2Δ showed this sensitivity to 2-
methoxybenzaldehyde, respectively.
The glr1Δ mutant did not show much sensitivity to
any of the compounds except for 3,5-dimethoxybenzal-
dehyde (Figure 2B). The sensitivity to this compound is
noteworthy because it suggests it disrupts cellular glu-
tathione (gamma-L-Glutamyl-L-Cysteinylglycine; a cellu-
lar antioxidant) homeostasis. The role of Glr1p
(glutathione reductase) is to replenish cellular GSH (a
reduced form of glutathione) by reducing GSSG (an oxi-
dized form of glutathione) [24]. We postulated the anti-
fungal action of 3,5-dimethoxybenzaldehyde resulted
from interference with the activity of Glr1p, which we
investigated further, described below.
The S. cerevisiae wild type and glr1Δ strains were pro-
vided with either GSH or GSSG in the presence of 3,5-
dimethoxybenzaldehyde (1.0 mM). Supplementation
with GSH (0.1 mM) almost completely recovered the
growth of both wild type and glr1Δ strains from the
toxicity of 3,5-dimethoxybenzaldehyde (Figure 2C).
However, supplementation with GSSG (0.1 mM) did not
result in growth-recovery. These results, the growth
recovery of the wild type and glr1Δ strains by GSH but
not by GSSG, further indicate 3,5-dimethoxybenzalde-
hyde disrupts cellular glutathione homeostasis by inter-
fering with Glr1p activity in fungi.
In summary, all seven of the “active” benzaldehydes
targeted the cellular antioxidation system, such as Cu,
Zn-SOD, Mn-SOD. In particular, one of them, 3,5-
dimethoxybenzaldehyde targeted Glr1p. It thus appears
these systems in fungi play an important role in
responding to and/or detoxifying these benzaldehydes.
Effect of benzaldehydes on fungal antioxidation: A.
fumigatus MAPK mutants
In yeasts, such as S. cerevisiae and Schizosaccharomyces
pombe, the regulation of SOD1, SOD2 and GLR1 genes
is controlled by the MAPK signaling pathway, such as
Hog1p [53]. SakA and MpkC in A. fumigatus are ortho-
logous proteins to Hog1p of S. cerevisiae [43,44]. A.
fumigatus sakAΔ is an osmotic/oxidative stress sensitive
mutant, while the mpkCΔ is a mutant of the polyalcohol
sugar utilization system [43,44]. Prior studies indicated
that SakA and MpkC MAPK pathways are differentially
regulated. None of the SakA-responsive cues tested,
such as oxidative stressors, resulted in a common phe-
notype for the mpkCΔ mutant [43,44]. Hence, it was
concluded that there were no overlapping roles between
SakA and MpkC pathways.
We studied the phenotypic responses of A. fumigatus
wild type and MAPK mutants, sakAΔ and mpkCΔ,t o
the seven benzaldehydes. We wanted to determine if
these compounds, like in S. cerevisiae, targeted the cel-
lular antioxidation system in a filamentous fungus.
Both mutants were more sensitive, showing no growth,
when treated with 0.8 mM 3,5-dimethoxybenzaldehyde
(Figure 2D). The wild type strain maintained some
growth, but with a 66% reduction in radial growth
compared to the control. Similarly, when treated with
2,5- or 2,3-dimethoxybenzaldehyde at 0.6 mM or 2.0
mM, respectively, the sakAΔ and mpkCΔ mutants
showed no growth, whereas the wild type showed only
a 42% or 58% reduced growth, respectively (Figure
data not shown). Other benzaldehydes also inhibited
the growth of the A. fumigatus MAPK mutants.
Amount of compound and Vincent equation % growth
inhibition compared to the wild type (AF293: sakAΔ:
mpkCΔ) are as follows: cinnamaldehyde at 0.4 mM
(42: 59: 76), o-vanillin at 0.3 mM (40: 88: 58), 2-
hydroxy-5-methoxybenzaldehyde at 0.4 mM (58: 65:
71), and 2-methoxybenzaldehyde at 0.8 mM (14: 16:
2 0 )( F i g u r ed a t an o ts h o w n ) .
Thus, similar to that of the antioxidation mutants of S.
cerevisiae (Figure 2B), the sakAΔ and mpkCΔ mutants
of A. fumigatus were more sensitive to the benzalde-
hydes than the wild type. These results also indicated
SakA and MpkC MAPK pathways may have overlapping
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hyde analogs.
Dimethyldithiocarbamate (DDC) is a Cu,Zn-SOD inhi-
bitor [54]. Since an equivalent mutant to S. cerevisiae
sod1Δ is not currently available in A. fumigatus,w er e a -
s o n e dt h a tt r e a t i n gA. fumigatus with DDC would che-
mically induce a phenotypic mimic of the S. cerevisiae
sod1Δ mutant. In a separate group of experiments, we
co-applied DDC with each of the seven benzaldehydes
(Groups A - C) against A. fumigatus AF293. Co-applica-
tion of the benzaldehyde derivatives with DDC increased
inhibition of fungal growth of the compounds alone, in
all combinations. These increases were from a low of
2% (DDC+ 2,3-dimethoxybenzaldehyde) to a high of
70% (DDC + 3,5-dimethoxybenzaldehyde), compared to
the level of growth inhibition from the compounds,
alone (Additional file 1 : TableS1). These increases of
growth inhibition under the co-application of the com-
pounds with an SOD inhibitor (DDC) were similar to
what we observed in the yeast dilution bioassays of the
compounds against the S. cerevisiae sod1Δ mutant (Fig-
ure 2B). There is one exception. While co-application of
2-methoxybenzaldehyde and DDC resulted in a 42%
increase of growth inhibition in A. fumigatus (Additional
file 1 : TableS1), the sod1Δ mutant was discernibly
insensitive to this compound (Figure 2B). This insensi-
tivity of the sod1Δ strain to 2-methoxybenzaldehyde
may reflect the weaker antifungal activity of this com-
pound compared to the other benzaldehydes identified.
The results with the S. cerevisiae mutants and with treat-
ment of the A. fumigatus wild type with DDC indicate that
both yeast and filamentous fungi respond similarly. In
both types of fungi the cellular antioxidation system is a
molecular target of the identified benzaldehyde analogs.
The verification of the response of both a yeast and fila-
mentous fungus to the benzaldehydes indicated the anti-
oxidation system is a promising target to debilitate in
order to increase effectiveness of fungal control agents.
Chemosensitization of phenylpyrrole fungicides: using
benzaldehydes to overcome fludioxonil tolerance of A.
fumigatus MAPK mutants
Certain fungi with mutations in genes involved in signal
transduction of stress response, MAPK signaling pathway,
can escape toxicity of the commercial fungicide fludioxonil
[55]. Fludioxonil is a phenylpyrrole compound having a
mode of action in fungi that triggers excessive stimulation
of the normal, intact MAPK signaling pathway for glycerol
biosynthesis [55]. The over-production of glycerol results
in an “energy drain” that eventually inhibits fungal growth.
We found sakAΔ and mpkCΔ, MAPK mutants of A. fumi-
gatus,t ob et o l e r a n tt o5 0μM fludioxonil, resulting in
only approximately 60% growth inhibition (Figure 3A).
However, co-application of sub-fungicidal levels of o-vanil-
lin with fludioxonil resulted in effective chemosensitiza-
tion. The o-vanillin plus fludioxonil pairing did not allow
these mutants to develop tolerance to fludioxonil, resulting
in 100% mortality (Figure 3A).
Other benzaldehydes from Groups A - C were also
tested for chemosensitization capacity in combination
with fludioxonil (Data not shown). These combinations
also resulted in loss of tolerance of these strains to fludiox-
onil. It is likely that benzaldehydes directly target genes in
the antioxidation system, such as Cu,Zn-SOD, Mn-SOD,
(A) (B)
Wild type
(AF293)
sakA
mpkC
No treatment o-Vanillin Fludioxonil
50 M
o-Vanillin+
Fludioxonil
MAPK pathway: sakA, mpkC
sakA
mpkC
Escape from
the toxicity of
fludioxonil
Fludioxonil
3,5-DMBA
Benzaldehyde
derivatives
GSH homeostasis: Glr1
Antioxidation: Sod1, Sod2
0.4 mM
0.4 mM
0.3 mM
0% 14% 100% 100%
0% 31% 100% 5917%
0% 10% 100% 7115%
Figure 3 Overcoming fludioxonil tolerance of A. fumigatus MAPK mutants (sakAΔ and mpkCΔ) by chemosensitization. (A)
Chemosensitization by using o-vanillin (%: Growth inhibition rate, SD < 5% except where noted). (B) Diagram showing the strategy for efficient
control of fungal pathogens by using screened benzaldehyde analogs. 3,5-DMBA, 3,5-Dimethoxybenzaldehyde.
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Page 9 of 16glutathione homeostasis, etc. These genes are downstream
of their respective MAPK signaling pathways [53,56].
Hence, the chemosensitization by the benzo analogs
results from bypassing the MAPK mutations and directly
stressing the fungal antioxidative system (e.g., enzymes,
etc.). The MAPK mutations, which had allowed tolerance
to fludioxonil, now, are unable to respond to additional
oxidative stress. This then results in inhibition of fungal
growth by redox-active benzaldehydes (Figure 3B).
Chemosensitization of inhibitors of complex II or III in
MRC by using benzaldehyde analogs
Next, we tested chemosensitizing activity of three ben-
zaldehyde analogs (the Group A compounds showing
the highest antifungal activity) in co-applications with
inhibitors, carboxin or AntA, of complex II or III,
respectively, the best targets in MRC (Figure 1B). Co-
treatment of cinnamaldehyde, o-vanillin or 2-hydroxy-5-
methoxybenzaldehyde with AntA (a complex III inhibi-
tor) mainly produced additive or synergistic interactions,
depending on the fungal strains (FICIs, Table 3). The
exceptions were A. flavus (cinnamaldehyde + AntA) or
A. fumigatus (all treatments), which yielded neutral
interactions.
Co-application of Group A compounds with carboxin (a
complex II inhibitor) showed less antifungal efficacy than
when co-applied with AntA (Table 3). All interactions
were additive in A. flavus. However, in the A. terreus
strains and P. expansum only additive or neutral interac-
tions occurred. As observed with the AntA co-applica-
tions, all interactions of the Group A benzo analogs with
carboxin tested in A. fumigatus were neutral. These results
indicate that MRC is probably a poorer target for chemo-
sensitization in A. fumigatus than in the other fungi.
Collectively, our results with the MRC inhibitors and co-
applied benzaldehydes show that the level of antifungal
interaction depends on species and strain of fungus tested.
However, overall, co-application of conventional MRC
inhibitors with certain natural benzaldehydes did result in
some promising interactions, i.e., synergistic/additive
(Table 3).
Benzaldehyde analogs as chemosensitizing agents to 2,3-
dihydroxybenzaldehyde or thymol, inhibitors of cell wall/
membrane integrity
In a prior study, two other natural phenolics, 2,3-dihy-
droxybenzaldehyde (2,3-D) and thymol, were found to
interfere with fungal cell wall/membrane integrity [46].
Based on this mode of action, we reasoned that the
newly identified benzaldehydes should be able to access
target sites in fungi more effectively when combined
with either 2,3-D or thymol. The chemosensitizing activ-
ities of the seven benzaldehydes were, thus, examined in
combination with 2,3-D and thymol in all six
filamentous fungal strains. The hypothesis was that
these combinations should result in higher, perhaps
even synergistic, antifungal activity.
Combinations of 2,3-D and the Group A - C benzalde-
hydes resulted in nine synergistic interactions with all
others being additive, depending on the compound and
strain (Additional file 2: TableS2). Hence, all of these co-
applications resulted in increased antifungal activities rela-
tive to the individual application of each compound, alone,
with no antagonistic or neutral interactions. Combinations
of 2,3-D with o-vanillin, 2-hydroxy-5-methoxy-, 2,3-
dimethoxy-, 2,5-dimethoxy- or 2-methoxy-benzaldehyde
resulted in at least one synergistic interaction. Some syner-
gistic interactions occurred with most of the Aspergillus
species/strains. All interactions with P. expansum or A.
terreus UAB698 were additive.
Combinations of thymol with the screened benzalde-
hyde analogs all resulted in additive interactions, with
the exception of cinnamaldehyde in A. flavus (synergis-
tic) (Additional file 3: TableS3). As with 2,3-D, our
results indicate that the identified benzaldehydes with
thymol increased antifungal activity of each compound
when combined, with no antagonistic or neutral
interactions.
Formulation studies: inhibition of fungal growth by using
mixtures of benzo analogs
Finally, we performed a formulation study of antifungal
activity against the filamentous fungi, in which only nat-
ural benzo analogs were used. The purpose of this
phase of our investigation was to determine if mixtures
of our already identified benzo analogs could yield an
effective level of antifungal activity, in vitro, against fun-
gal pathogens, without a conventional antifungal drug.
Formulations included the cell wall/membrane inhibi-
tory compounds, 2,3-D and thymol, with the three
Group A benzaldehydes (o-vanillin, 2-hydroxy-5-meth-
oxybenzaldehyde and cinnamaldehyde).
Antifungal activities (i.e., MICs, MFCs, FEMICs,
FEMFCs; See Methods) of each of the benzo analogs,
individually and combined as a formulation, against
each of the strain/species of filamentous fungus tested
are summarized in Table 4. In all cases, when each
compound was applied individually, higher concentra-
tions (viz., higher MICs) were required for the complete
inhibition of fungal growth compared to the combina-
tion of all compounds in formulations. In some cases
complete inhibition of fungal growth was not achieved
at the highest concentration tested (128 μg/ml) by the
individual compounds. MICs (microtiter) for the indivi-
dual compounds were as follows: 64 μg/ml (o-vanillin,
2-hydroxy-5-methoxybenzaldehyde, cinnamaldehyde) for
all strains; > 128 μg/ml (thymol) for all strains; 16 μg/
ml (2,3-D) for A. fumigatus AF293/A. terreus UAB673;
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Page 10 of 16Table 3 Antifungal interactions (FICI) of benzaldehyde derivatives tested alone or in combination with antimycin A or carboxin in microtiter plates
1
Compounds MIC alone MIC combined FICI MIC: alone MIC: combined FICI MIC: alone MIC: combined FICI
Strains A. terreus UAB698 A. terreus UAB680 A. terreus UAB673
Cinnamaldehyde
Antimycin A
0.2 - 0.4
> 128
2
0.1 - 0.2
8-1 6
0.56 A 0.2 - 0.4
> 128
0.1 - 0.2
4-8
0.53 A 0.2 - 0.4
> 128
0.1 - 0.2
4-8
0.53 A
o-Vanillin
Antimycin A
0.2 - 0.4
> 128
0.1 - 0.2
4-8
0.53 A 0.2 - 0.4
> 128
0.1 - 0.2
4-8
0.53 A 0.2 - 0.4
> 128
0.1 - 0.2
4-8
0.53 A
2-Hydroxy-5-methoxy
Antimycin A
0.2 - 0.4
> 128
0.1 - 0.2
64 - 128
1.00 A 0.2 - 0.4
> 128
0.1 - 0.2
8-1 6
0.56 A 0.2 - 0.4
> 128
0.1 - 0.2
8-1 6
0.56 A
Strains A. flavus NRRL3357 A. fumigatus AF293 P. expansum NRRL974
Cinnamaldehyde
Antimycin A
0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.05 - 0.1
8-1 6
0.31 S
o-Vanillin
Antimycin A
0.2 - 0.4
> 128
0.1 - 0.2
16 - 32
0.63 A 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.05 - 0.1
4-8
0.28 S
2-Hydroxy-5-methoxy
Antimycin A
0.2 - 0.4
> 128
0.1 - 0.2
64 - 128
1.00 A 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.05 - 0.1
4-8
0.28 S
Strains A. terreus UAB698 A. terreus UAB680 A. terreus UAB673
Cinnamaldehyde
Carboxin
0.2 - 0.4
> 128
2
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N
o-Vanillin
Carboxin
0.2 - 0.4
> 128
0.1 - 0.2
64 - 128
1.00 A 0.1 - 0.2
> 128
0.1 - 0.2
> 128
2.00 N 0.2 - 0.4
> 128
0.1 - 0.2
64 - 128
1.00 A
2-Hydroxy-5-methoxy
Carboxin
0.2 - 0.4
> 128
0.1 - 0.2
64 - 128
1.00 A 0.2 - 0.4
> 128
0.1 - 0.2
32 - 64
0.75 A 0.2 - 0.4
> 128
0.1 - 0.2
16 - 32
0.63 A
Strains A. flavus NRRL3357 A. fumigatus AF293 P. expansum NRRL974
Cinnamaldehyde
Carboxin
0.4 - 0.8
> 128
0.2 - 0.4
64 - 128
1.00 A 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.1 - 0.2
64 - 128
1.00 A
o-Vanillin
Carboxin
0.4 - 0.8
> 128
0.2 - 0.4
64 - 128
1.00 A 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.4 - 0.8
> 128
0.2 - 0.4
16 - 32
0.63 A
2-Hydroxy-5-methoxy
Carboxin
0.4 - 0.8
> 128
0.2 - 0.4
32 - 64
0.75 A 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N 0.2 - 0.4
> 128
0.2 - 0.4
> 128
2.00 N
1Compound interactions were determined as Fractional Inhibitory Concentration Indices (FICI), described by Isenberg ([47]; See also Methods). For calculation purposes, the higher concentration in each column was
used. A, additive; N, neutral; S, synergistic. Benzaldehyde derivatives (mM)- cinnamaldehyde, o-vanillin, 2-hydroxy-5-methoxybenzaldehyde; Complex II inhibitor (μg/ml)- Carboxin; Complex III inhibitor (μg/ml)-
Antimycin A.
2Since antifungal test was performed up to 128 μg/ml of antimycin A or carboxin (See Methods), 256 μg/ml (doubling of 128 μg/ml) was used for calculation purposes.
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632 μg/ml (2,3-D) for A. terreus UAB680; 64 μg/ml (2,3-
D) for A. terreus UAB698/P. expansum NRRL974; 128
μg/ml (2,3-D) for A. flavus NRRL3357 (Table 4). How-
ever, formulations, which included mixtures of all five
compounds, completely inhibited the growth of A. fumi-
gatus AF293 or A. terreus UAB673 at an MIC of 4-8
μg/ml of each compound combined. Slightly higher
MICs (8-16 μg/ml of each compound) were needed to
achieve complete growth inhibition of A. terreus
UAB680/UAB698, A. flavus NRRL3357 or P. expansum
NRRL974 (Table 4).
On the other hand, complete fungal kill (MFC) was
not truly achieved with almost any of the compounds,
individually (all MFCs > 128 μg/ml). The only exception
was for cinnamaldehyde where the MFC was 64-128 μg/
ml for all fungi except for P. expansum where the MFC
was 32-64 μg/ml. However, when combined in formula-
tions, all fungi were completely killed at an MFC of 16-
32 μg/ml. Based on ratios of MFCs vs.M I C so ft h ef o r -
mulations (i.e., MFCFORMULATION/MICFORMULATION ≤ 4;
See Table 4), all formulations were classified as “fungici-
dal” against all strains. The MICs of the formulations
were, in some cases, > 10 times lower than those of the
compounds treated individually. Hence, combining these
benzo analogs in a formulation achieved in vitro anti-
fungal activity equivalent or within an order of magni-
tude (at a μg/ml level) to that of currently available
antifungal drugs (e.g., [57]).
Lastly, the potential contribution to formulation effi-
cacy (FEMIC or FEMFC reflecting individual compound
antifungal activity vs. in a formulation; See Methods) of
the individual compounds was calculated to be high (H)
(FEs ≥ 4) for cinnamaldehyde, o-vanillin, 2-hydroxy-5-
methoxybenzaldehyde, 2,3-D and thymol in almost all
cases (Table 4). The only exceptions were the FEMICso f
2,3-D for A. fumigatus AF293, A. terreus UAB673/
Table 4 Fungicidal efficacy of benzaldehyde formulations (μg/ml) against individual strains of filamentous fungi
examined
1
Compounds alone
Cinnamaldehyde o-
Vanillin
2-Hydroxy-5-
methoxybenzaldehyde
2,3-D Thymol Formulation
(combined)
Fungicidality MFCFORMULATION/
MICFORMULATION
A.
fumigatus
AF293
MIC
(FEMIC)
MFC
(FEMFC)
32-64
(8 H)
64-128
(4 H)
32-64
(8 H)
> 128
(8 H)
32-64
(8 H)
> 128
(8 H)
8-16
(2 L)
> 128
(8 H)
> 128
2
(32 H)
N/D
3
(8 H)
4-8
16-32
4 (Fungicidal)
4
A. terreus
UAB673
MIC
(FEMIC)
MFC
(FEMFC)
32-64
(8 H)
64-128
(4 H)
32-64
(8 H)
> 128
(8 H)
32-64
(8 H)
> 128
(8 H)
8-16
(2 L)
> 128
(8 H)
> 128
(32 H)
N/D
(8 H)
4-8
16-32
4 (Fungicidal)
A. terreus
UAB680
MIC
(FEMIC)
MFC
(FEMFC)
32-64
(4 H)
64-128
(4 H)
32-64
(4 H)
> 128
(8 H)
32-64
(4 H)
> 128
(8 H)
16-32
(2 L)
> 128
(8 H)
> 128
(16 H)
N/D
(8 H)
8-16
16-32
2 (Fungicidal)
A. terreus
UAB698
MIC
(FEMIC)
MFC
(FEMFC)
32-64
(4 H)
64-128
(4 H)
32-64
(4 H)
> 128
(8 H)
32-64
(4 H)
> 128
(8 H)
32-64
(4 H)
> 128
(8 H)
> 128
(16 H)
N/D
(8 H)
8-16
16-32
2 (Fungicidal)
A. flavus
NRRL3357
MIC
(FEMIC)
MFC
(FEMFC)
32-64
(4 H)
64-128
(4 H)
32-64
(4 H)
> 128
(8 H)
32-64
(4 H)
> 128
(8 H)
64-
128
(8 H)
> 128
(8 H)
> 128
(16 H)
N/D
(8 H)
8-16
16-32
2 (Fungicidal)
P.
expansum
NRRL974
MIC
(FEMIC)
MFC
(FEMFC)
32-64
(4 H)
32-64
(2 L)
32-64
(4 H)
> 128
(8 H)
32-64
(4 H)
> 128
(8 H)
32-64
(4 H)
> 128
(8 H)
> 128
(16 H)
N/D
(8 H)
8-16
16-32
2 (Fungicidal)
1 Efficacy of combined compounds compared to each compound alone is expressed as Formulation Efficacy (FEMIC or FEMFC; See Methods). FEMIC, FE for MIC
values; FEMFC, FE for MFC values; H (high) if FE ≥ 4, L (low) if 1 < FE < 4; See Methods for calculations. For calculation purposes, higher concentration (μg/ml) of
each concentration range was used for FE determination (e.g., 64 from 32 - 64 μg/ml).
2Assays were conducted up to a highest concentration of 128 μg/ml. For calculation purposes, 256 μg/ml (doubling of 128 μg/ml) was used.
3ND: Not determined since fungal growth occurred at the highest concentration (128 μg/ml). For calculation purposes, 256 μg/ml was used.
4Fungicidal or fungistatic effect was determined based on MFCFORMULATION/MICFORMULATION ratio (Fungicidal if ≤ 4, fungistatic if > 4; See Methods for calculations).
For calculation purposes, higher concentration (μg/ml) of each MIC or MFC range was used.
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Page 12 of 16UAB680 or FEMFCso fc i n n a m a l d e h y d ef o rP. expansum
NRRL974, where the values were low (L) (≤ 2).
Discussion
Collectively, the results of this study show that certain
benzaldehyde analogs can act as potent antifungal agents,
or as chemosensitizing agents in concert with conven-
tional antimycotic products, to augment their efficacy.
Based on fungal gene deletion mutant bioassays, the ben-
zaldehydes studied target the fungal cellular antioxidation
system, including MAPK signaling or the antioxidation
enzymes, Cu,Zn-SOD, Mn-SOD, or glutathione reductase.
These benzaldehydes also enhance, as chemosensitizing
agents, the in vitro activity of conventional antifungal che-
micals, such as MRC inhibitors or phenylpyrrole agents,
and also natural phenolics such as 2,3-D and thymol in
filamentous fungi. Co-application of benzaldehydes with
other antifungal drugs, or applied in formulations of only
the benzaldehydes, resulted in complete inhibition of fun-
gal growth at much lower doses than any of the individual
components applied, alone. Use of these benzaldehydes as
chemosensitizing agents overcomes fungal tolerance to
conventional fungicides, such as fludioxonil, and lowers
dosage levels of conventional antifungal agents required
for effective control.
Many antimicrobial drugs can disrupt the cellular
antioxidation system of fungi. In this regard, such drugs
can be considered as oxidative stress agents. Examples
include MRC inhibitors and GSH depleting agents. For
instance, C9-UK-2A, a structural derivative of AntA,
showed potent antifungal activity against fungal patho-
gens, including S. cerevisiae [21,58]; pathogenic strains
of S. cerevisiae have been isolated [58]. This drug trig-
gers membrane injury, and induces the generation of
cellular ROS against Rhodotorula mucilaginosa cells.
C9-UK-2A inhibited the vegetative growth of S. cerevi-
siae, which also accompanies cellular and mitochondrial
ROS generation [21]. This generation of ROS was due
to the inhibition of electron flow at complex III in
MRC. Meanwhile, treatment of fungal cells with
dimethyldithiocarbamic acid or thiram [bis
(dimethylthiocarbamoyl) disulfide] resulted in a rapid
decrease in the level of cellular GSH, an important cel-
lular antioxidant [59]. Consequently, the decrease in
GSH will result in oxidative stress to fungi.
Other types of fungal oxidative stress agents include
the phenylpyrroles, such as fludioxonil. In fungi, detec-
tion of environmental stresses, such as osmotic or oxi-
dative stress, or cell wall disruption, is integrated into
MAPK signaling pathways, which regulate downstream
genes that are responsible for countering the stress
[60,61]. Noteworthy is that mutations in fungal MAPK
pathways, or upstream two-component (His-Asp phos-
phorelays) signaling systems, which relay environmental
cues to the MAPK system, can result in tolerance to
antifungal agents [55,62,63]. For example, fludioxonil
interferes with fungal signaling systems resulting in
excessive stimulation of the intact histidine kinase (HK)-
MAPK stress-response pathway or glycerol biosynthesis
[55,64,65]. This stimulation is akin to the osmotic stress
response, which is also linked to cellular oxidative stress
([66] and references therein). However, studies have
shown that if there is a mutation in the HK-MAPK sig-
naling system, a fungus becomes resistant to fludioxonil
[55,64]. Hence, an intact MAPK system is required for
these types of fungicides to be effective. The sakAΔ and
mpkCΔ MAPK mutants of A. fumigatus we used in our
study are vivid examples of how such mutants can be
tolerant to phenylpyrroles. However, we were able to
show that by applying an oxidative stress agent (such as
one of the benzaldehydes), these tolerant strains became
susceptible because their mutated MAPK system was
incapable of launching a fully operational oxidative
stress response.
Involvement of stress-inducible protein(s) in drug
resistance has already been documented [67,68]. The
heat shock protein Hsp90, an essential molecular cha-
perone and key regulator of cell signaling, regulates
folding, transport, maturation, and degradation of cellu-
lar proteins [69-71]. In both S. cerevisiae and the oppor-
tunistic yeast pathogen Candida albicans,H s p 9 0
potentiates rapid evolution of drug resistance to azoles
[68]. Alternatively, drug resistance was abrogated by
applying inhibitors of Hsp90 [67]. Hsp90 production is
induced under stress, but availability of this protein may
dwindle as there is increased cellular demand as the
stress continues [72].
The scenario with Hsp90 is conceptually analogous to
our findings presented here. As mentioned earlier, the
fungal antioxidation enzymes, such as Cu,Zn-SOD, Mn-
SOD, glutathione reductase, etc., are necessary to con-
tend with adverse conditions generated by oxidative
stress drugs (e.g., MRC inhibitors). Accordingly, cellular
demand for these enzymes can continuously increase as
more and more oxidative stress is applied. Hence,
redox-active benzaldehydes, such as those in our study,
can be useful chemosensitizing agents when co-applied
with oxidative stress drugs. In this case the fungal anti-
oxidation system would be overwhelmed because levels
of antioxidation enzymes would not be sufficient for
detoxification of the concerted activities of multiple oxi-
dative stress agents (e.g., oxidative stress drug + redox-
active chemosensitizers). Future studies may warrant a
phenotypic-response screening of the entire set of dele-
tion mutants of S. cerevisiae to the benzaldehydes.
There is a possibility of other cellular targets to these
compounds, in addition to the antioxidation system
identified in our study.
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also be toxic to mammalian cells. For example, TTFA (a
complex II inhibitor) can directly decrease cellular
respiration, and disrupt mitochondrial membrane poten-
tial in mammalian cells [73]. Also, TTFA delays cell
cycle progression, which leads to an increase of cellular
ROS, glutathione oxidation and a decrease in cellular
ATP levels [73]. Similarly, AntA (a complex III inhibi-
tor) inhibits mitochondrial respiration in rat liver cells,
and increases production of cellular ROS ([74] and
references therein). However, potential side effects of
MRC inhibitors as antifungal agents can be reduced if
effective dosage levels of MRC inhibitors can be dimin-
i s h e d .S u c har e d u c t i o nc a nb ea c h i e v e db yu s eo f
redox-active natural phenolics as chemosensitizers to
MRC inhibitors, as shown in our study.
MRC inhibitors can also be used to enhance antifun-
gal drugs. For example, co-application of MRC inhibi-
tors with the antifungal drug, caspofungin (an inhibitor
of cell wall integrity), greatly increased susceptibility of
Candida parapsilosis to caspofungin [75]. Contrastingly,
inducing the alternative respiratory pathway in MRC
results in decreasing the susceptibility of C. albicans to
antifungal triazole drugs [76]. Thus, use of MRC inhibi-
tors (along with chemosensitizing agents) should be
considered further for effective control of human
mycoses. Another form of fungal defense, involving mul-
tidrug resistance, can also be disrupted to enhance anti-
fungal activity. For example, in strains of S. cerevisiae
where multidrug resistant genes PDR1, PDR3,o rPDR5
are mutated, there is increased sensitivity to mucidin, an
MRC inhibitor [20].
Conclusions
Cellular antioxidation systems appear to be promising
molecular targets of natural phenolics for the effective
control of fungi. Benzaldehyde analogs, such as those iden-
tified in this study, can be used as potent chemosensitizing
agents to enhance anitmycotic activity of already available
antifungal drugs. Our study focused on the effects of the
tested benzaldehydes against the selected filamentous
fungi. They also showed similar effects on the strains of S.
cerevisiae, used in our study to examine mode of action.
However, it is likely these benzaldehydes would have simi-
lar activity against pathogenic yeasts, such as Candida spe-
cies and Cryptococcus neoformans. Certain benzaldehydes
were recently reported to have chemosensitizing activity,
in combination with certain antifungal drugs (amphoteri-
cin B, triazoles), against reference strains of C. albicans
and C. neoformans [77]. Correspondingly, the benzalde-
hydes examined in our study, here, have potent antifungal
activity against clinical strains of these yeasts (manuscript
in preparation). Such chemosensitization can reduce costs,
lower resistance, and alleviate health risks associated with
current antifungal therapy. Further in vivo studies are
necessary to determine if the in vitro activities demon-
strated herein can translate to clinically effective and safe
chemotherapeutic resolution of mycoses.
Additional material
Additional file 1: Table S1. Enhanced growth inhibition of
Aspergillus fumigatus AF293 by co-application of benzaldehyde
derivatives and diethyldithiocarbamate (DDC)
1.
1 Number in each
column indicates % inhibition of fungal radial growth, which was based
on Vincent equation (See Methods) (SD < 5%). Diethyldithiocarbamate
(DDC): Cu,Zn-SOD (Cytosolic superoxide dismutase) inhibitor.
2 The value
of % increase by co-application (i.e., compound + DDC) = (Vincent eq.
value from co-application) - (Vincent eq. value from independent
treatment, i.e., compound or DDC alone, showing higher % growth
inhibition).
Additional file 2: Table S2. Antifungal interactions (FICI) of 2,3-
dihydroxybenzaldehyde (2,3-D; mM) and other benzaldehyde
derivatives (mM) tested alone or in combination in microtiter
plates
1.
1 Compound interactions were determined as Fractional
Inhibitory Concentration Indices (FICI), described by Isenberg ([47]; See
Methods). For calculation purposes, the higher concentration in each
column was used. A, additive; N, neutral; S, synergistic.
Additional file 3: Table S3. Antifungal interactions (FICI) of thymol
(mM) and benzaldehyde derivatives (mM) tested alone or in
combination in microtiter plates
1.
1 Compound interactions were
determined as Fractional Inhibitory Concentration Indices (FICI), described
by Isenberg ([47]; See Methods). For calculation purposes, the higher
concentration in each column was used. A, additive; N, neutral; S,
synergistic.
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